-transparent.png){kind=logo}
High-dose chemotherapy and/or total body irradiation followed by autologous bone marrow rescue has improved the survival of patients with a variety of malignancies. Candidates for autologous bone marrow transplantation (ABMT) often have received prior exposure to cytotoxic agents, some of which may damage primitive stem cells. We have developed an in vivo murine model to evaluate the effects of a number of individual cytotoxic agents on the ability of syngeneic donor marrow to provide long-term hematopoiesis in recipients following high-dose total body irradiation. Marrow was experimentally obtained by giving donor mice 6 weekly injections of saline, cytosine arabinoside, cyclophosphamide, cisplatin, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), or busulfan, drugs known to have differing effects on primitive hematopoietic stem cells. After time to allow recovery of marrow and peripheral blood counts, 1 x 10(7) marrow cells from these mice were transplanted into lethally irradiated syngeneic recipients. Five to 6 months after marrow transplantation, the quality of long-term hematopoietic recovery was measured by WBC counts, marrow cellularity, CFU-S content, and determinations of stem cell self-renewal. Abnormalities were noted with the use of donor marrow exposed to all cytotoxic agents. Recipients of marrow previously exposed to cytosine arabinoside, an agent that spares the most primitive stem cells, were the least affected. Recipients of marrow previously exposed to busulfan, an agent known to damage primitive stem cells, were most affected with a decrease in peripheral blood counts, marrow cellularity, stem cell content, self-renewal capacity, and long-term survival. A decrease in hematopoietic stem cell self-renewal was seen in recipients of marrow previously exposed to cyclophosphamide, cisplatin, and BCNU even when marrow cellularity and CFU-S content were normal. These data suggest that the capacity of syngeneic donor marrow to provide long-term hematopoiesis in lethally irradiated recipients is dependent on its donor marrow primitive stem cell content. Long-term hematopoiesis may be severely compromised in recipients of donor stem cells previously exposed to cytotoxic agents which damage primitive stem cells.
S Neben, and
S Hellman, and
M Montgomery, and
J Ferrara, and
P Mauch, and
S Hemman
April 2006,
Seikagaku. The Journal of Japanese Biochemical Society,
S Neben, and
S Hellman, and
M Montgomery, and
J Ferrara, and
P Mauch, and
S Hemman
July 2017,
International journal of hematology,
S Neben, and
S Hellman, and
M Montgomery, and
J Ferrara, and
P Mauch, and
S Hemman
December 2008,
La Revue du praticien,
S Neben, and
S Hellman, and
M Montgomery, and
J Ferrara, and
P Mauch, and
S Hemman
January 1978,
Experimental hematology,
S Neben, and
S Hellman, and
M Montgomery, and
J Ferrara, and
P Mauch, and
S Hemman
January 2016,
Current topics in developmental biology,
S Neben, and
S Hellman, and
M Montgomery, and
J Ferrara, and
P Mauch, and
S Hemman
February 2018,
Journal of cellular physiology,
S Neben, and
S Hellman, and
M Montgomery, and
J Ferrara, and
P Mauch, and
S Hemman
November 2014,
Der Internist,
S Neben, and
S Hellman, and
M Montgomery, and
J Ferrara, and
P Mauch, and
S Hemman
September 1972,
Transplantation,
S Neben, and
S Hellman, and
M Montgomery, and
J Ferrara, and
P Mauch, and
S Hemman
October 2010,
Experimental hematology,
S Neben, and
S Hellman, and
M Montgomery, and
J Ferrara, and
P Mauch, and
S Hemman
March 2009,
Proceedings of the National Academy of Sciences of the United States of America,
